USA - engelsk - NLM (National Library of Medicine)

b. braun medical inc. - hydroxyethyl starch 130/0.4 (unii: 1gvo236s58) (hydroxyethyl starch 130/0.4 - unii:1gvo236s58), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - hydroxyethyl starch 130/0.4 6 g in 100 ml - 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection is indicated for the treatment and prophylaxis of hypovolemia in adults and children. it is not a substitute for red blood cells or coagulation factors in plasma. - do not use hydroxyethyl starch (hes) products, including 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, in critically ill adult patients, including patients with sepsis, due to increased risk of mortality and renal replacement therapy (rrt).  - do not use hes products, including 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, in patients with severe liver disease. - do not use hes products, including 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, in patients with known hypersensitivity to hydroxyethyl starch [see general warnings and precautions (5.1) ] - do not use hes products in clinical conditions with volume overload.  - do not use hes products in patients with pre-existing coagulation or bleeding disorders.  - do not use h

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - hydroxyethyl starch 130/0.4, quantity: 60 g/l - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of voluven is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - hydroxyethyl starch 130/0.4, quantity: 60 g/l - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid; sodium chloride - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of voluven is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - hydroxyethyl starch 130/0.4, quantity: 60 g/l - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of voluven is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - hydroxyethyl starch 130/0.4, quantity: 60 g/l - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; sodium chloride - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of voluven is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

USA - engelsk - NLM (National Library of Medicine)

hospira, inc. - hydroxyethyl starch 130/0.4 (unii: 1gvo236s58) (hydroxyethyl starch 130/0.4 - unii:1gvo236s58) - hydroxyethyl starch 130/0.4 6 g in 100 ml - voluven ® (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is indicated for the treatment and prophylaxis of hypovolemia in adults and children. it is not a substitute for red blood cells or coagulation factors in plasma. - do not use hydroxyethyl starch (hes) products, including voluven ® , in critically ill adult patients, including patients with sepsis, due to increased risk of mortality and renal replacement therapy (rrt). - do not use hes products, including voluven ® , in patients with severe liver disease. - do not use hes products, including voluven ® , in patients with known hypersensitivity to hydroxyethyl starch [see general warnings and precautions (5.1) ] - do not use hes products in clinical conditions with volume overload. - do not use hes products in patients with pre-existing coagulation or bleeding disorders. - do not use hes products in patients with renal failure with oliguria or anuria not related

USA - engelsk - NLM (National Library of Medicine)

zoetis inc. - hydroxyethyl starch 130/0.4 (unii: 1gvo236s58) (hydroxyethyl starch 130/0.4 - unii:1gvo236s58) - hydroxyethyl starch 130/0.4 6000 mg in 100 ml - vetstarch™ (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is indicated for the treatment and prophylaxis of hypovolemia. it is not a substitute for red blood cells or coagulation factors in plasma. the use of vetstarch™ is contraindicated in the following conditions: • known hypersensitivity to hydroxyethyl starch [see general warnings and precautions (5.1)]  • fluid overload (hyperhydration) and especially in cases of pulmonary edema and congestive heart failure • renal failure with oliguria or anuria not related to hypovolemia • patients receiving dialysis treatment • severe hypernatremia or severe hyperchloremia • intracranial bleeding the type of hydroxyethyl starch present in vetstarch had no teratogenic properties in rats or rabbits. at 5 g/kg of body weight per day, administered as a bolus injection, fetal retardations and embryolethal effects were observed in rats and rabbits, respectively. in rats, a bolus injection of this dose during pregnancy and lactation reduced body

USA - engelsk - NLM (National Library of Medicine)

b. braun medical inc. - hetastarch (unii: 875y4127ea) (hetastarch - unii:875y4127ea), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - hetastarch 6 g in 100 ml - hespan® is indicated in the treatment of hypovolemia when plasma volume expansion is desired in settings where adequate alternative treatment is unavailable. it is not a substitute for blood or plasma. the adjunctive use of hespan® in leukapheresis has also been shown to be safe and efficacious in improving the harvesting and increasing the yield of granulocytes by centrifugal means. - do not use hes products, including hespan®, unless adequate alternative treatment is unavailable. hetastarch has been shown to have an embryocidal effect on new zealand rabbits when given intravenously over the entire organogenesis period in a daily dose 1/2 times the maximum recommended therapeutic human dose (1500 ml) and on bd rats when given intraperitoneally, from the 16th to the 21st day of pregnancy, in a daily dose 2.3 times the maximum recommended therapeutic human dose. when hetastarch was administered to new zealand rabbits, bd rats, and swiss mice with intravenous daily doses of 2 times, 1/3 times, and 1 times the m

USA - engelsk - NLM (National Library of Medicine)

hospira, inc. - hetastarch (unii: 875y4127ea) (hetastarch - unii:875y4127ea) - 6% hetastarch in 0.9% sodium chloride injection is indicated in the treatment of hypovolemia when plasma volume expansion is desired in settings where adequate alternative treatment is unavailable. it is not a substitute for blood or plasma. the adjunctive use of 6% hetastarch in 0.9% sodium chloride injection in leukapheresis has also been shown to be safe and efficacious in improving the harvesting and increasing the yield of granulocytes by centrifugal means. do not use hes products, including 6% hetastarch in 0.9% sodium chloride injection, unless adequate alternative treatment is unavailable. hetastarch has been shown to have an embryocidal effect on new zealand rabbits when given intravenously over the entire organogenesis period in a daily dose 1/2 times the maximum recommended therapeutic human dose (1500 ml) and on bd rats when given intraperitoneally, from the 16th to the 21st day of pregnancy, in a daily dose 2.3 times the maximum recommended therapeutic human dose. when hetastarch was administered

USA - engelsk - NLM (National Library of Medicine)

vedco, inc. - hydroxyethyl starch 130/0.4 (unii: 1gvo236s58) (hydroxyethyl starch 130/0.4 - unii:1gvo236s58) - hydravol iv™ acts as plasma volume substitute for the treatment and prophylaxis of hypovolemia. it is not a substitute for red blood cells or coagulation factors in plasma. the use of hydravol iv™ is contraindicated in the following conditions: - known hypersensitivity to hydroxyethyl starch. - fluid overload (hyperhydration) and especially in cases of pulmonary edema and congestive heart failure. - renal failure with oliguria or anuria not related to hypovolemia. - patients receiving dialysis treatment. - severe hypernatremia or severe hyperchloremia. - intracranial bleeding.